8 Reproductive & Developmental Tox (DART) CROs

What is Reproductive & Developmental Tox (DART) and when do you need it?

DART is the part of your safety package that asks a narrow but consequential question: can this drug damage fertility, a developing embryo or fetus, or an offspring after birth. The work is organized into three classic segments that follow the reproductive cycle. Fertility and early embryonic development (often called Segment I, ICH stages A and B) doses adults before and through mating to look at sperm, ovaries, mating behavior, and implantation. Embryo-fetal development, the EFD or Segment II study (stages C and D), dposes pregnant animals through organogenesis and examines fetuses for malformations and growth effects; this is run in two species, conventionally the rat and the rabbit. Pre- and postnatal development, the PPND or Segment III study (stages E and F), follows treated mothers through delivery and weaning to catch effects on labor, lactation, and the next generation. The governing guideline is ICH S5(R3).

Here is the part that trips up first-time sponsors: DART is rarely on the critical path to your very first dose, but its timing is a real regulatory decision, not an afterthought. Under ICH M3(R2), you can usually enroll men and women not of childbearing potential in early Phase 1 without any DART data, and you can enroll a limited number of women of childbearing potential (WOCBP) on effective contraception with preliminary embryo-fetal data, deferring the definitive EFD studies. To include WOCBP more broadly, or to keep them in longer trials, you need the full fertility and EFD package, with PPND typically required before Phase 3 or registration. Regions differ: some jurisdictions take a more conservative line and expect EFD data earlier than the FDA does.

Because the rules hinge on your trial population rather than the molecule alone, the smart move is to settle DART timing at your pre-IND meeting before you commit budget. Get the agency's read on when WOCBP enter the trial, what preliminary data they will accept, and whether your modality changes the picture. A clear answer here decides whether DART is a fast follow or a study you book months ahead.

What does a Reproductive & Developmental Tox (DART) CRO actually do?

A DART CRO runs the in-life animal studies and the specialized assessments that general toxicology labs are not set up for. The fertility study covers dosing, mating, cesarean evaluation, and counts of corpora lutea, implantations, and resorptions, plus sperm analysis in males. The EFD study, the heart of most packages, requires fetal examination skills that are genuinely specialized: external, visceral, and skeletal exams on large numbers of fetuses, with staining and microdissection to read malformations and variations reliably. The PPND study adds the operational burden of letting dams litter and rear pups, then testing the offspring for developmental landmarks, reflexes, learning, and their own reproductive capacity.

Around the in-life work, the CRO handles the parts that make the data filable: a validated dose formulation and analysis, toxicokinetic sampling so exposure can be tied to any effect seen, board-certified reproductive pathology, statistical analysis, and a study report written to support your IND. The rabbit is the standard second species for EFD, and a lab that runs rabbit work routinely, with historical control data on malformation background rates, is worth more than one improvising it. For biologics where the rat and rabbit are not pharmacologically relevant, the work often shifts to the non-human primate, an enhanced pre/postnatal development (ePPND) design that is longer, costlier, and run by a much shorter list of labs.

Almost all of this is GLP work because it feeds human risk assessment, though preliminary or dose-range-finding DART studies can run non-GLP to set doses before the pivotal studies. The deliverable you are buying is not just animals dosed: it is a defensible exposure-to-effect story, a NOAEL for reproduction and development, and a report a reviewer can map onto your trial population.

How to choose a Reproductive & Developmental Tox (DART) CRO?

DART is a specialty within toxicology, so the right filter is demonstrated reproductive-tox experience and clean regulatory track record, not the lowest bid. A repeated or rejected study here is the multi-month, six-figure delay you are trying to avoid, and the species and fetal-evaluation skills are not interchangeable with general tox capacity. Score two or three candidates against the same written scope and weight the items below.

• Quality and GxP status: confirm GLP (21 CFR Part 58, or OECD GLP for ex-US) for every pivotal study, ask for recent FDA or inspection history, and get the named study director in writing, since the study director owns the GLP study and the report.
• Capacity and lead time: rabbit and non-human-primate slots are the binding constraint far more often than the science. Pin down a milestone timeline (protocol, dosing cohorts, cesarean or littering, fetal evaluation, draft and final report) and ask what historically causes slippage.
• Modality and indication fit: small molecules usually run rat plus rabbit EFD, but biologics frequently need an ePPND in non-human primates, and ADCs, oligonucleotides, and advanced therapies each carry their own design questions. Match the lab to your modality before price.
• Region and regulatory track record: confirm the lab has supported submissions to the agencies you are filing with (FDA, EMA, PMDA, NMPA), because regional expectations on EFD timing and design differ.
• Data quality: look for board-certified reproductive pathology, deep historical control data on background malformation and variation rates, validated dose-formulation analysis, and toxicokinetics built into the studies so exposure ties to any finding.
• IP and confidentiality: settle ownership of data and reports, sample and tissue handling, and confidentiality terms before signing, especially if the program or target is undisclosed.